A Phase 3 trial of esmethadone as adjunctive treatment for patients with treatment‐resistant depression did not meet its primary endpoint of significant improvement in depressive symptoms at 28 days compared with placebo. Esmethadone did show significant improvement over placebo in treatment response rate.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: